FindTrial
Sign In

A single-arm clinical study of osimertinib induction followed by concurrent radiotherapy in the treatment of inoperable stage III EGFR-mutated non-small cell lung cancer

A single-arm clinical study of osimertinib induction followed by concurrent radiotherapy in the treatment of inoperable stage III EGFR-mutated non-small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098806
Enrollment
Unknown
Registered
2025-03-13
Start date
2025-03-13
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage III unresectable EGFR-mutated non-small cell lung cancer

Interventions

Experimental Group:Included patients received oral osimertinib 80 mg once daily for 8 weeks (28 days X2). After evaluation, osimertinib 80 mg orally once daily was administered concurrently with radio

Sponsors

Jilin Chemical Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Age range: 20-70 years old; 2.Histologically confirmed unresectable stage III non-small cell lung cancer with EGFR exon 19 deletion or exon 21 L858R substitution mutation; 3.The World Health Organization (WHO) performance status score is 0 or 1.

Exclusion criteria

Exclusion criteria: 1.EF<=50%; 2.WBC<=3.0×10^9/l;HGB<=90g/l,PLT <=80×10^9/l.

Design outcomes

Primary

MeasureTime frame
Objective response rate;—

Countries

China

Contacts

Public ContactGuangchao Zhang

Jilin Chemical Hospital

jlgmdzgc@163.com+86 432 63961394

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026